SC5: USE AND TROUBLESHOOTING OF EUKARYOTIC EXPRESSION SYSTEMS
MONDAY, 18 NOVEMBER | MORNING, 09:00 - 12:00
Room 1.08
ABOUT THIS COURSE: Eukaryotic expression systems are extensively used for the generation of recombinant proteins thereby becoming an essential protein engineering tool. The choice of a suitable eukaryotic expression system depends mainly
on the biological and biochemical properties of an individual protein. The course will focus on both the insect and mammalian expression systems, which have demonstrated the ability to express complex proteins for a wide variety of applications. We
will discuss the concepts, uses, and optimization of these systems along with sharing experimental troubleshooting lessons learned. The course combines instruction and case studies in an interactive environment.
COURSE AGENDA:
09:00 Opening Remarks/Introductions
Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
09:05 Insect Expression Systems
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
09:50 Mammalian Expression Systems
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
10:35 Coffee Break
11:05 Implementing Eukaryotic Expression Systems
Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
12:00 Close of Course
INSTRUCTOR BIOGRAPHY:
Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
Rich Altman has 30 years of experience in protein expression and production. In early 2019, he joined Thermo Fisher Scientific as a Field Application Scientist. Previously, he worked for several pharmaceutical companies, including Amgen, Alexion, Bayer, and Upjohn, on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years, he has worked as a principal scientist and now in product development and portfolio management
for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior
to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on providing production of Ras and Ras-related proteins for the National Cancer Institute’s
RAS Initiative. These proteins are being used for a wide-ranging attack on Ras biology including structural biology, biophysics, and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins
of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his PhD in Biochemistry
at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.